DCF Valuation Model for Invex Therapeutics, page-149

Velocity of recruitment is probably most important as it is a good indicator of what doctors unrelated to the company think (given that they are responsible for referring patients to the trial). Usually the price would have started moving up already, although the current market conditions aren't very conducive to speculation so that's why we are seeing a bit of a delay with the share price. I do find it strange though that the market has failed to adjust the price of this company considering the fact that the drug has been approved before. Obviously it meets the safety criteria already, which does derisk this company quite substantially. Efficacy is where the gamble is, though I feel considering the fact we are at phase III already and safety is confirmed, the current price offers a great risk/reward. Despite the extremely low market cap, It is still a pretty big gamble though imo, which is why my position is not very large at all. If this doesn't work out there isn't really much of a plan b. Nonetheless, if this does work out the potential returns off such a low market cap could be enormous